A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

BACKGROUND: Bevacizumab, an antibody neutralizing Vascular Endothelial Growth Factor (VEGF), is licensed for the management of patients with advanced colon cancer. However, tumor biomarkers identifying the molecular tumor subsets most amenable to angiogenesis modulation are lacking. METHODS: We prof...

Descripción completa

Detalles Bibliográficos
Autores principales: Pentheroudakis, George, Kotoula, Vassiliki, Fountzilas, Elena, Kouvatseas, George, Basdanis, George, Xanthakis, Ioannis, Makatsoris, Thomas, Charalambous, Elpida, Papamichael, Demetris, Samantas, Epaminontas, Papakostas, Pavlos, Bafaloukos, Dimitrios, Razis, Evangelia, Christodoulou, Christos, Varthalitis, Ioannis, Pavlidis, Nicholas, Fountzilas, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933361/
https://www.ncbi.nlm.nih.gov/pubmed/24555920
http://dx.doi.org/10.1186/1471-2407-14-111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933361/
https://www.ncbi.nlm.nih.gov/pubmed/24555920
http://dx.doi.org/10.1186/1471-2407-14-111

Ejemplares similares